Continued success for Lynparza in ovarian cancer
The drug improved progression-free survival time to a median of 22.1 months, compared to 16.6 months.
Read More
Tag: European Society of Medical Oncology
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
- eXmoor Pharma and UCL establish strategic cell and gene therapy collaboration
- Miranda Dini launches GOLD amid industry shifts
